ViMRT
}  
 
Home   
< Docs   

 HIV mutation literature information.


  Identification of alternative amino acid substitutions in drug-resistant variants of the HIV-1 reverse transcriptase.
 PMID: 16847406       2006       AIDS (London, England)
Abstract: Phenotypic analysis indicated that drug-resistance properties of the alternative Y181V and L74I mutants are similar, but not identical, to that of the well-known Y181C and L74V mutations.


  Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903.
 PMID: 16925730       2006       HIV medicine
Abstract: In the d4T arm, a variety of NRTI mutations developed: K65R (n = 2), L74V (n = 2), V75M (n = 1), and T69A + Y115H (n = 1).


  High Prevalence of Abacavir-associated L74V/I Mutations in Kenyan Children Failing Antiretroviral Therapy.
 PMID: 16931138       2006       Journal of clinical virology
Abstract: Analysis of 73 clones (patient 1: 12 clones; patient 2: 27 clones; patient 3: 13 clones; patient 4: 21 clones) showed that 29 clones harboured K65R and L74V/I mutations.
Abstract: OBJECTIVE: To determine to which extent the mutations K65R, L74V/I and T215Y/F are linked to the same HIV-1 genome.


  Cytotoxic T cell recognition of an HIV-1 reverse transcriptase variant peptide incorporating the K103N drug resistance mutation.
 PMID: 16970827       2006       AIDS research and therapy
Result: In another study, epitopes incorporating M41L, L74V, M184V and T215Y in RT were demonstrated by ELISPOT.


  In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine.
 PMID: 16982781       2006       Antimicrobial agents and chemotherapy
Abstract: Abacavir resistance was characterized by the accumulation of the M184V, Y115F, and K65R mutations in the abacavir culture, while the M184V and L74V mutations were selected in combination with lamivudine.


  Differential impact of thymidine analogue mutations on emtricitabine and lamivudine susceptibility.
 PMID: 17075395       2006       Journal of acquired immune deficiency syndromes (1999)
Abstract: For samples with K65R, L74I/V, or Q151M mutations, the phenotypic impact was similar, as the mean fold-change was not significantly different between drugs.


  Impact of HIV-1 reverse transcriptase polymorphism at codons 211 and 228 on virological response to didanosine.
 PMID: 17310813       2006       Antiviral therapy
Abstract: A mutation score (M41L+D67N+T69D-K70R +L74V-M 1 84V/I+T21 5Y/F+ K219Q/E+ R211A/D/G/K/S+ L228H/M/R), including two RT polymorphisms not previously described to be associated with ddl resistance (211 and 228) and RT mutations previously described, was associated with a continuum of virological response and increased the predictability of virological response to ddl.


  Early virological failure in treatment-naive HIV-infected adults receiving didanosine and tenofovir plus efavirenz or nevirapine.
 PMID: 15668550       2005       AIDS (London, England)
Abstract: At month 6, the mutations detected were K65R, L74V, L100I, K103N/R/T, Y181C and G190E/Q/S.


  Early virological failure with a combination of tenofovir, didanosine and efavirenz.
 PMID: 15751775       2005       Antiviral therapy
Abstract: Additionally, L74V/I and K65R were detected in four and two patients, respectively.


  Relationship between drug resistance mutations, plasma viremia, and CD4+ T-cell counts in patients with chronic HIV infection.
 PMID: 15778973       2005       Journal of medical virology
Abstract: In the univariate analysis, a lower viral load (P < 0.0001), the presence of drug-resistant viruses (P = 0.038), and specific mutations in the reverse transcriptase (RT) gene [presence of M184V (P = 0.016) or K70R (P < 0.0001), and lack of L74V (P < 0.003)] were all associated with higher CD4+ counts.



Browser Board

 Co-occurred Entities




   Filtrator